EXEL Stock Analysis: Exelixis | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 16.403m USD | 12M Return: 78.2% | US30161Q1040 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 137M
EPS Trend: 94.8%
Qual. Beats: 1
Rev. Trend: 95.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Exelixis, Inc. is a U.S.-based oncology biopharmaceutical company headquartered in Alameda, California, focused on discovering, developing, and commercializing treatments for difficult-to-treat cancers. The companys commercial portfolio is anchored by CABOMETYX and COMETRIQ, both derived from its lead compound cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, RET, and VEGF receptors. Additional marketed products include COTELLIC, a MEK inhibitor used in combination therapy for advanced melanoma, and MINNEBRO, a mineralocorticoid receptor blocker for hypertension that is sold in Japan through a partner.
Beyond its approved medicines, Exelixis maintains a pipeline of oncology therapies in earlier stages of development, including zanzalintinib (an oral kinase inhibitor), XL309 (a USP1 inhibitor targeting BRCA-mutated tumors), and several antibody-drug conjugates and bispecific antibody candidates such as XB010, XB628, and XB371. The company operates a hybrid business model common to mid-to-large biotechnology firms, combining direct commercialization of its lead products in the United States with licensing and collaboration agreements covering international markets. It has research, development, and commercialization partnerships with major pharmaceutical companies including Ipsen, Takeda, Roche/Genentech, Bristol-Myers Squibb, and Daiichi Sankyo, which extend the reach of its approved products and support pipeline development. Exelixis was incorporated in 1994 and completed its IPO in 2000.
- CABOMETYX franchise revenue growth sustains US oncology sales
- Zanzalintinib and ADC pipeline readouts diversify beyond cabozantinib
- Renal cell carcinoma competition intensifies from IO-TKI combinations
| Net Income: 885.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.46 > 0.02 and ΔFCF/TA 19.48 > 1.0 |
| NWC/Revenue: 36.44% < 20% (prev 44.95%; Δ -8.51% < -1%) |
| CFO/TA 0.47 > 3% & CFO 1.17b > Net Income 885.1m |
| Net Debt (-729.8m) to EBITDA (1.08b): -0.68 < 3 |
| Current Ratio: 3.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (255.8m) vs 12m ago -8.18% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 93.57% > 50% (prev 81.04%; Δ 12.53% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.36 (Total Current Assets 1.32b - Total Current Liabilities 411.9m) / Total Assets 2.51b |
| B: -0.10 (Retained Earnings -258.8m / Total Assets 2.51b) |
| C: 0.39 (EBIT TTM 1.05b / Avg Total Assets 2.67b) |
| D: 2.70 (Book Value of Equity 1.83b / Total Liabilities 679.7m) |
| Altman-Z'' = 7.51 = AAA |
| DSRI: 0.97 (Receivables 328.5m/309.7m, Revenue 2.50b/2.29b) |
| GMI: 1.00 (GM 96.63% / 96.26%) |
| AQI: 1.17 (AQ_t 0.44 / AQ_t-1 0.38) |
| SGI: 1.09 (Revenue 2.50b / 2.29b) |
| TATA: -0.11 (NI 885.1m - CFO 1.17b) / TA 2.51b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of October 31, 2026, the stock is trading at USD 69.39 with a total of 5,063,269 shares traded. Over the past week, the price has changed by +7.53%, over one month by +18.31%, over three months by +23.98% and over the past year by +78.20%.
Current recommended Stop Loss: 67.60 (which is 2.6% or 1.1 ATR below the current price).
Exelixis has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold EXEL.
- StrongBuy: 6
- Buy: 1
- Hold: 10
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 55.5 | -20% |
P/E Trailing = 20.8833
P/E Forward = 15.4799
P/S = 6.7339
P/B = 8.9093
P/EG = 2.2685
Revenue TTM = 2.50b USD
EBIT TTM = 1.05b USD
EBITDA TTM = 1.08b USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 162.2m USD (from shortLongTermDebtTotal, last quarter) (leases 162.2m already included)
Net Debt = -729.8m USD (calculated: Debt 162.2m - CCE 892.0m)
Enterprise Value = 15.7b USD (16.4b + Debt 162.2m - CCE 892.0m)
Interest Coverage Ratio = unknown (Ebit TTM 1.05b / Interest Expense TTM 0.0)
EV/FCF = 13.60x (Enterprise Value 15.7b / FCF TTM 1.15b)
FCF Yield = 7.35% (FCF TTM 1.15b / Enterprise Value 15.7b)
FCF Margin = 46.14% (FCF TTM 1.15b / Revenue TTM 2.50b)
Net Margin = 35.45% (Net Income TTM 885.1m / Revenue TTM 2.50b)
Gross Margin = unknown ((Revenue TTM 2.50b - Cost of Revenue TTM 93.3m) / Revenue TTM)
Tobins Q-Ratio = 6.24 (Enterprise Value 15.7b / Total Assets 2.51b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 162.2m)
Taxrate = 16.95% (180.7m / 1.07b)
NOPAT = 871.2m (EBIT 1.05b * (1 - 16.95%))
Current Ratio = 3.21 (Total Current Assets 1.32b / Total Current Liabilities 411.9m)
Debt / Equity = 0.09 (Debt 162.2m / totalStockholderEquity, last quarter 1.83b)
Debt / EBITDA = -0.68 (Net Debt -729.8m / EBITDA 1.08b)
Debt / FCF = -0.63 (Net Debt -729.8m / FCF TTM 1.15b)
Total Stockholder Equity = 1.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 33.17% (Net Income 885.1m / Total Assets 2.51b)
RoE = 45.54% (Net Income TTM 885.1m / Total Stockholder Equity 1.94b)
RoCE = 49.92% (EBIT 1.05b / Capital Employed (Total Assets 2.51b - Current Liab 411.9m))
RoIC = 44.07% (NOPAT 871.2m / Invested Capital 1.98b)
WACC = 8.14% (E(16.4b)/V(16.6b) * Re(8.22%) + D(162.2m)/V(16.6b) * Rd(0.0%) * (1-Tc(0.17)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.64 | Cagr: -6.00%
[DCF] Terminal Value 77.97% ; FCFF base≈988.9m ; Y1≈1.13b ; Y5≈1.67b
[DCF] Fair Price = 104.3 (EV 25.1b - Net Debt -729.8m = Equity 25.8b / Shares 247.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.77 | EPS CAGR: 65.79% | SUE: 0.94 | # QB: 1
Revenue Correlation: 95.80 | Revenue CAGR: 11.43% | SUE: 0.40 | # QB: 0
EPS current Year (2026-12-31): EPS=3.58 | Chg30d=+0.06% | Revisions=-17% | GrowthEPS=+16.4% | GrowthRev=+10.1%
EPS next Year (2027-12-31): EPS=4.27 | Chg30d=+0.31% | Revisions=+29% | GrowthEPS=+19.2% | GrowthRev=+13.6%
[Analyst] Revisions Ratio: +10% (up=4, down=3)